Candel Therapeutics, Inc. - CADL Net Assets per Single Share

Public company logo of Candel Therapeutics (CADL)

Serving as a valuation tool, the Candel Therapeutics (CADL) price chart demonstrates the dynamics of a company whose medical center deliveries rely on strict protocol compliance and reliable cooling systems. The brand maintains high authority in developing safe viral methods for combating tumors. Meanwhile, financial stability is constrained by R&D expenditures, and the current metric stands at 1.66, pending the commercial success of its developments.

Candel (CADL) - Accounting Value per Share from 07/04/2022 to 10/27/2026

Summary analytical data breakdowns for Candel Therapeutics Inc. (CADL)

- price and consensus price forecast:
Stock Price Candel|CADL - Broker Consensus Forecast
- market capitalization data:
Market Value Candel Therapeutics, Inc.|CADL - Total Company Value
- book capitalization data:
Book Value per Share Candel Therapeutics|CADL - Company Net Assets|Market Capitalization to Book Value Ratio candeltx.com|CADL - Company Total Assets
- debt and liquidity data:
Debt to Equity Candel Therapeutics|CADL - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Candel|CADL - Company Total Debt|Debts to Book Capitalization Candel Therapeutics, Inc.
Analysis of all company metrics:candeltx.com, CADL
Manufactured product of Candel Therapeutics Inc.

The high demand potential for Candel Therapeutics (CADL) oncolytic therapies necessitates an evaluation of the capital base via the net asset value per share ratio. This metric measures the company's residual value after deducting liabilities, confirming the business's asset stability; by analyzing the historical book value per share, an investor can determine the risk of price overvaluation relative to actual fundamental backing.

Competitor analysis for Candel Therapeutics

BeiGene Corp (ONC) - Book Value per Share|HALO: Equity per Share|Revolution Medicines (RVMD) - Net Assets per Single Share|ascentage.com (AAPG) - Net Assets per Single Share|Book Value per Share CGON|Accounting Value per Share UroGen Pharma Ltd|Book Value per Share BCAX|Book Value per Share PSNL (Personalis Genomics)|ERAS - Net Assets per Single Share|Equity per Share delcath.com DCTH|YMAB: Book Value per Share|AURA - Accounting Value per Share|Book Value per Share ARAY|SLS (SELLAS Life Sciences Group) - Net Asset Value per Share|ACTU - Net Assets per Single Share|Accounting Value of a Share citiusonc.com (CTOR)|TuHURA Biosciences, Inc. (HURA) - Accounting Value per Share|Accounting Value of a Share Protara Therapeutics Inc (TARA)|Fate Therapeutics Corp - Book Value per Share|WHWK - Accounting Value per Share|TScan - Accounting Value per Share|CSBR: Book Value per Share|Net Assets per Single Share xbiotech.com XBIT|CEL-SCI (CVM) - Accounting Value of a Share|Book Value per Share OSTX (OS Therapies Inc)|Net Asset Value per Share radiopharmtheranostics.com|Book Value per Share ARTV (Artiva Biotherapeutics, Inc.)|Accounting Value per Share adlainortye.com (ANL)|Book Value per Share VERU (Veru)|Tempest Therapeutics Inc - Book Value per Share|Xilio (XLO) - Net Assets per Single Share|RENB - Equity per Share|Book Value per Share muraloncology.com|Kairos Pharma (KAPA) - Equity per Share|Book Value per Share OKUR (OnKure Therapeutics, Inc.)|Net Asset Value per Share GDTC|Net Assets per Single Share Curis, Inc. (CRIS)|Net Assets per Single Share apollomicsinc.com APLM|Accounting Value per Share Tharimmune, Inc.|ADVB - Accounting Value of a Share|Accounting Value per Share Genprex GNPX|CLDI - Book Price of a Share|Book Value per Share Sunshine Biopharma, Inc. SBFM|Xenetic Biosciences, Inc. (XBIO) - Accounting Value of a Share|Book Value per Share SLRX (Salarius Pharmaceuticals)|Net Asset Value per Share PPBT|American Oncology Network (AONC) - Net Assets per Single Share|Accounting Value of a Share BeiGene Ltd. (BGNE)|Book Value per Share CKPT (Checkpoint Therapeutics, Inc)|elevationoncology.com - Book Value per Share|Net Assets per Single Share iCAD Corp|IKNA - Share Book Value|Book Value per Share NTBL|Net Asset Value per Share Viracta Therapeutics, Inc.|MOR (MorphoSys Corp) - Accounting Value per Share|Book Value per Share NAYA Biosciences Corp (NAYA)|Accounting Value per Share Ascentage Pharma Group